Trials / Completed
CompletedNCT03234660
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia
The Effects of Dexmedetomidine on the Neurotoxicity From General Anesthesia Assessed by Plasma Glial Fibrillary Acidic Protein
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Seoul National University Hospital · Academic / Other
- Sex
- All
- Age
- 1 Month – 3 Years
- Healthy volunteers
- Not accepted
Summary
Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in several settings of neuronal injury in animals. We hypothesized that neuroprotective effect of dexmedetomidine would be associated with evidence of brain injury detected by elevation of plasma concentration of glial fibrillary acid protein in children undergoing general anesthesia.
Detailed description
GFAP measure
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine Hydrochloride | dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery |
| OTHER | control | 0.9% normal saline continuous infusion |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2019-10-05
- Completion
- 2019-10-05
- First posted
- 2017-07-31
- Last updated
- 2020-01-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03234660. Inclusion in this directory is not an endorsement.